Site Editor
Soo Park, MD
Soo Park, MD
Posted: Monday, November 11, 2024
Lilit Karapetyan, MD, MS, FACP, of H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, and colleagues conducted a pooled efficacy analysis of tumor-infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma. Their findings were presented during the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (Abstract 450).
The investigators focused on 60 patients who were enrolled in four phase I/II clinical trials of TIL therapy alone (32%) and in combination with ipilimumab (22%), nivolumab (18%), and vemurafenib (28%). A total of 16.7% of the population did not receive an infusion. Among those who did, 72% had an elevated level of lactate dehydrogenase (LDH), 34% had liver metastases, 18% had brain metastases, and 24% previously received immune checkpoint blockade. The median numbers of infused TIL and interleukin (IL)-2 doses were 59 x 109 and 5, respectively. Follow-up data were provided for a median of 102 months.
In the intention-to-treat population, the median progression-free survival was 7 months, and the median overall survival was 31 months. These durations were 10 and 52 months, respectively, in the patients who received TIL therapy. The objective response rate was 36%, with a complete response rate of 14%.
The level of LDH, previous treatment, and number of IL-2 doses were not found to be associated with response. A trend toward lack of response was seen in patients with liver metastases (P = .05). According to the investigators, the total number of infused TILs was associated with improved progression-free survival (hazard ratio = 0.26; P = .003). Patients who achieved an objective response were found to have a higher proportion of CD8 cells in the infusion product (89% vs 54%; P = .003) and a peak absolute lymphocyte count after treatment (6 vs 3 k/mL; P = .03). The response rate to immune checkpoint blockade after disease progression with adoptive cell therapy was 19%.
Disclosure: No information regarding conflicts of interest was provided.
JNCCN Spotlights
Resources
For your Patients
